Infection

New Expanded, Updated Edition of OnePoint Patient Care Clinical Symptom Guide Now Available

Thursday, September 23, 2021 - 7:39pm

TEMPE, Ariz., Sept. 23, 2021 (GLOBE NEWSWIRE) -- OnePoint Patient Care has published a newly updated and vastly expanded 3rd edition of its Clinical Symptom Guide.

Key Points: 
  • TEMPE, Ariz., Sept. 23, 2021 (GLOBE NEWSWIRE) -- OnePoint Patient Care has published a newly updated and vastly expanded 3rd edition of its Clinical Symptom Guide.
  • OnePoint Patient Care's clinical team also collaborated with experts in infectious disease and pediatric endocrinology/neurology to develop five new monographs on infectious disease and five on pediatrics.
  • "This guide represents a massive leap forward in terms of educating our staff and partners, and enhancing patient care."
  • Hospices also frequently use the guide in clinical interdisciplinary team meetings, training and other applications focused on improving care for hospice patients.

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

Thursday, September 23, 2021 - 7:01pm

TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.

Key Points: 
  • TB202-3 binds to a specific area (RBD-4) of the SARS-CoV-2 spike protein that has not been impacted by most viral mutations.
  • This makes it an important and viable candidate for clinical testing in combination with other antibody therapeutics.
  • TB202-3 binds to a majority of known mutations, with the exception of the L452R mutation present in the Delta and Epsilon variants.
  • Target recognition by VHH single domains, on the other hand, requires just a single domain found on heavy chain only antibody.

US's Leading Tick-Borne Disease Lab IGeneX Supports Research for a Cure

Thursday, September 23, 2021 - 6:33pm

MILPITAS, Calif., Sept. 23, 2021 /PRNewswire/ --IGeneX, a leading tick-borne disease and COVID-19 testing lab, is pleased to announce their longstanding support of the Annual LDA Scientific Conference this October, "21st annual CME scientific conference, Lyme & Other Tick-Borne Diseases: Research for a Cure."

Key Points: 
  • MILPITAS, Calif., Sept. 23, 2021 /PRNewswire/ --IGeneX, a leading tick-borne disease and COVID-19 testing lab, is pleased to announce their longstanding support of the Annual LDA Scientific Conference this October, "21st annual CME scientific conference, Lyme & Other Tick-Borne Diseases: Research for a Cure."
  • Such knowledge stimulates novel research ideas, forges collaborations, and enhances critical clinical care.
  • IGeneX joins the Alexandra Cohen Foundation in sponsoring the Annual LDA Scientific Conference in 2021.
  • IGeneX is passionate about supporting factual and relevant education to medical professionals," said Dr. Jyotsna Shah, Ph.D., President and Laboratory Director of IGeneX. "

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

Thursday, September 23, 2021 - 1:00pm

Michael S. Weiss, the Companys Chairman and Chief Executive Officer stated, We are pleased that the integrated safety analysis of 371 patients treated with UKONIQ has been published in Blood Advances.

Key Points: 
  • Michael S. Weiss, the Companys Chairman and Chief Executive Officer stated, We are pleased that the integrated safety analysis of 371 patients treated with UKONIQ has been published in Blood Advances.
  • The integrated safety data analysis of umbralisib published [today/yesterday] is encouraging for patients, especially given the low rate of discontinuations due to adverse events observed.
  • These data are described further in the manuscript entitled, Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies, which was published online in Blood Advances.
  • UKONIQ is a trademark ofTG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.

Immuron planned Acquisition of R&D Vaccine Company

Thursday, September 23, 2021 - 2:00pm

The Company has been pursuing a major acquisition of a private biotechnology company focused on the development of innovative vaccine technologies.

Key Points: 
  • The Company has been pursuing a major acquisition of a private biotechnology company focused on the development of innovative vaccine technologies.
  • The Immuron Board of Directors considered that this acquisition opportunity would have added significant value to the Company and shareholders potentially delivering a much-needed Australian developed COVID-19 vaccine candidate for commercialization.
  • The ASX has absolute discretion to re-admit a company to the official list after such a transaction has occurred.
  • As a result of Immuron not proceeding with the proposed acquisition at this time.

Global Infectious Disease Molecular Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Thursday, September 23, 2021 - 3:28pm

The "Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Technology (PCR, ISH, INAAT), By End-use, By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infectious Disease Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents), By Technology (PCR, ISH, INAAT), By End-use, By Application, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global infectious disease molecular diagnostics market size is expected to reach USD 40.8 billion by 2028, according to a new report by the publisher.
  • The market is driven by the introduction of technologically advanced products and an increase in demand for molecular diagnostics in PoC settings.
  • Rapid technological advancements with portability, accurate results, and cost-effectiveness are anticipated to serve as crucial drivers of the market for infectious disease molecular diagnostics.

Worldwide Network Point-of-Care Glucose Testing Industry to 2028 - Growing Focus on Diabetes Care is Driving the Market - ResearchAndMarkets.com

Thursday, September 23, 2021 - 3:24pm

Increasing demand for safe and accurate remote patient monitoring options and the need for data-based treatment regimens are major factors driving the market.

Key Points: 
  • Increasing demand for safe and accurate remote patient monitoring options and the need for data-based treatment regimens are major factors driving the market.
  • The integration of advanced technologies including Bluetooth Low Energy (BLE) and Infrared is expected to fuel the market growth in the upcoming years.
  • Expanding patient base in Asia Pacific and the Middle East and the high demand for advanced diabetes management systems are creating significant growth opportunities in these regions.
  • Increasing demand for world-class healthcare services and rising adoption of advanced technology are some of the factors boosting the market growth in these regions.

Come For The Music, Get An Optional COVID Jab Or Test At Miramar Latin Music Festival

Thursday, September 23, 2021 - 4:09pm

Both the vaccines and the PCR tests, the gold standard for detecting COVID-19 infection, will be offered at no cost to individuals.

Key Points: 
  • Both the vaccines and the PCR tests, the gold standard for detecting COVID-19 infection, will be offered at no cost to individuals.
  • The tests and vaccinations are optional and not a requirement for attending the event.
  • COVID test management software company to offer tests and vaccines at Miramar music fest at no cost Saturday, Sept 25.
  • An individual self-schedules a test or vaccination from a mobile device, which can be done in person at the Miramar event.

U.S. Dept. of Health and Human Services Taps Draper to Develop Lung-on-a-Chip Technology to Study SARS-CoV-2

Thursday, September 23, 2021 - 3:00pm

With the contract, Draper will design a model for human airway tissue and adapt its PREDICT96 platform to collect data for SARS-CoV-2 infection studies.

Key Points: 
  • With the contract, Draper will design a model for human airway tissue and adapt its PREDICT96 platform to collect data for SARS-CoV-2 infection studies.
  • The study of respiratory health, diseases and treatments is typically done through animal studies or culture models using animal or human cells.
  • BARDA's ImmuneChip+ program requires that all applicants already have a mature, validated tissue chip, in this case the lung.
  • To develop an organ-on-a-chip, human cells are used to manufacture 3D organ-like structures.

Hydromer, Inc. Surpasses the 40-Year Mark as a World-Wide Supplier of Specialty Coatings for Medical and Industrial Applications and Announces That Its New Facility in North Carolina is Fully Operational With Extensive New Capabilities

Thursday, September 23, 2021 - 2:00pm

Coatings that can be heat or UV-cured, in solvent and water base versions to accommodate any type of coating requirements.

Key Points: 
  • Coatings that can be heat or UV-cured, in solvent and water base versions to accommodate any type of coating requirements.
  • Very large, modular ISO-class 8 clean room to accommodate customers devices of various sizes and quantities, including capabilities to coat devices up to 20-FT (600 CM) in length.
  • Expertise in coating complex devices like balloons, intricate IDs, multi-lumen and others, including emerging 3-D printed parts used in device development.
  • For the latest information about Hydromer, Inc. and its products, please visit our web site at www.hydromer.com or contact us atinfo@hydromer.com.